PORTEC 3, 2018

Question 1

Study question for PORTEC 3?

Answer 1

Adjuvant chemo during and after RT vs pelvic RT alone for high risk endometrial cancer (high risk features have a risk of recurrence)

Question 2

PORTEC 3 study type?

Answer 2

RCT, n=636

Question 3

PORTEC 3 inclusion criteria?

Answer 3

High risk -Stage 1, endometrioid G3 with deep MI or LVSI or both, Stage 2 or 3 endometrioid or any serous or clear cell

Question 4

Arms of PORTEC 3?

Answer 4

RT, chemoRT, cisplatinRT + 4 cycles carbo/taxol

Question 5

Conclusions of PORTEC 3?

Answer 5

11% improvement in failure free survival, no improvement in OS in overall cohort, as well as Stage III or serous histology

Toxicity and QOL worse in first year in patients with combined therapy

Later follow up (2019) - SS improvement in 5y OS (81% in chemoRT vs 76% in RT alone)

By Stage – OS only seen in patients with Stage III disease and serous

Question 6

Molecular analysis of PORTEC 3

Answer 6

Greatest benefit of chemoRT vs chemo alone; summary benefit in patients with p53mut (36-59%) with chemoRT at ALL stages of disease

May have been from adding chemo and not just chemoRT (there was not chemo alone group to compare)